Selvigaltin (GB1211), an orally readily available small molecule galectin-3 inhibitor designed as a cure for liver fibrosis and cirrhosis, was evaluated to evaluate the outcome of hepatic impairment on its pharmacokinetics and security to handle regulatory specifications. Desk 4 Statistical assessment of dose proportionality of the pharmacokinetic parameters of GB1211 https://annez604sag6.gynoblog.com/profile